Oragenics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- $7M
- Website
- http://www.oragenics.com
A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
Phase 2
Not yet recruiting
- Conditions
- Mild Traumatic Brain Injury, Concussion
- Interventions
- Drug: Neurosteroid enantiomer
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06870240
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Phase 2
Terminated
- Conditions
- Oral Mucositis
- Interventions
- Biological: AG013Other: Placebo
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03234465
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸Comprehensive Cancer Centers of Nevada-Henderson, Henderson, Nevada, United States
🇺🇸East Carolina Univ School of Dental Medicine, Greenville, North Carolina, United States
Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)
Not Applicable
- Conditions
- Oral Health
- Interventions
- Other: ProBiora3 mintsOther: Placebo tablet
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01520974
- Locations
- 🇺🇸
University of Washington, Scool of Dentistry, Regional Clinical Dental Research Center, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath